Sleep Better Columbus is now offering FDA-cleared oral appliance therapy for patients diagnosed with mild to moderate ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

Explore the rising trend of mouth taping during sleep, analyzing its potential risks and minimal benefits for breathing and ...

A recent post-hoc analysis of the SURMOUNT-OSA trials revealed that tirzepatide significantly improves obstructive sleep ...

If you struggle with 'mouth breathing' while you sleep, from the occasional snore or full-blown obstructive sleep apnea, you ...

CI Insights From Zepbound to AD109, pharma innovation is reshaping Obstructive Sleep Apnea. Discover key players, C ...

“REM sleep is when your brain does some of its most important cleanup and memory storage work,” said co-corresponding author ...

Obstructive Sleep Apnea (OSA) remains a widespread yet under-treated condition, affecting millions globally. Traditional treatments such as CPAP therapy, w | Drug Discovery And Development ...

Logistic regression analysis showed that only AHI was a predictor of daytime hypercapnia ... daytime hypercapnia may be directly linked to sleep apnea in a subgroup of patients with OSAS.

Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice-nightly oxybate to once-at-bedtime LUMRYZ – – Data ...

With the FDA authorization in place, Incannex will initiate Phase 3 immediately following the completion of Phase 2, leveraging a shared protocol and U.S. based infrastructure to maximize efficiency ...